Search Results 1831-1840 of 19666 for Hemoglobin

  1. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  2. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  3. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    * Diffusing Capacity (of Lung) for Carbon Monoxide (DLCO) >=25% of predicted normal corrected for hemoglobin (Hb). * Prebronchodilator Forced Expiratory ...

  4. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL - Mayo Clinic

    Adequate hematology (Hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 ´ 109/L, platelets ≥100 x 109/L) without ongoing transfusional support; Adequate renal and liver ...

  5. A Study to Evaluate Ribociclib Plus Letrozole to Treat Cancer of the Ovary, Fallopian Tube or Peritoneum - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL;; Potassium, total calcium (corrected for serum albumin), magnesium, sodium and phosphorus within normal limits for the institution or ...

  6. Vinorelbine Tartrate and Cyclophosphamide in Combination with Bevacizumab or Temsirolimus in Treating Patients with Recurrent or Refractory Rhabdomyosarcoma - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL (may receive packed red blood cells [PRBC] transfusions); Bone marrow disease involvement of tumor is allowed, however, peripheral ...

  7. A Study to Evaluate the Safety and Effectiveness of Obeticholic Acid Treatment on People with Non-Alcoholic Steatohepatitis with Fibrosis - Mayo Clinic

    Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria (hemoglobin A1c [HbA1c] ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2-hour ...

  8. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

    Hemoglobin ≥ 8 g/dL; participants with chronic anemia (other than autoimmune hemolytic anemia) that is supported by intermittent red blood cell ...

  9. A Study Comparing Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia - Mayo Clinic

    Evidence of progressive marrow failure as manifested by the development of worsening anemia (hemoglobin [Hg] < 11 g/dl) and/or thrombocytopenia (platelets < 100 ...

  10. Study of BLU-667 in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors - Mayo Clinic

    Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 ...